XML 43 R4.htm IDEA: XBRL DOCUMENT v3.20.1
Consolidated Statements of Operations - USD ($)
 12 Months Ended
Dec. 31, 2019
Dec. 31, 2018
Income Statement [Abstract]    
Technology development and licensing revenue $ 500,000 $ 500,000
Operating expenses:    
Research and development 13,065,309 11,865,523
General and administrative 8,000,164 9,699,521
Total operating expenses 21,065,473 21,565,044
Loss from operations (20,565,473) (21,065,044)
Other income (expense):    
Gain from change in earn-out milestone liability 3,189,955 3,630,861
Fair value of warrants issued in connection with amendment to modify GEN-1 earn-out milestone payments (400,000)
Impairment of in-process research and development (4,510,000)
Investment income, net 500,882 353,682
Interest expense (1,393,400) (712,025)
Other income 29 52
Total other income (expense) 1,897,466 (1,237,430)
Net loss before income tax benefit (18,668,007) (22,302,474)
Income tax benefit 1,816,474 10,419,115
Net loss $ (16,851,533) $ (11,883,359)
Net loss per common share - basic and diluted $ (0.77) $ (0.68)
Weighted average common shares outstanding - basic and diluted 21,832,932 17,582,879